CST3 and cancer: Some clinical studies demonstrate increased levels of serum cystatin C in patients with active cancer, namely, breast, head and neck, lung, colorectal, prostate, and kidney cancers.20 However, these studies lacked adjustment for mGFR and assessment of other non-GFR determinants.